Disc Medicine (IRON) Stock
Cell therapy developer for degenerative spinal disc conditions. Here's the price, business snapshot, and what's worth knowing about Disc Medicine in August 2026.
Disc Medicine Inc (ticker: IRON) is a clinical-stage biotechnology company working on cell-based therapies for degenerative spinal disc conditions and related musculoskeletal disorders. With a market capitalisation of about $3.0 billion, the company’s progress is typically driven by clinical trial results, regulatory interactions and partnership or licensing activity. For investors, the key considerations include the science behind its therapeutic approach, the timing and outcome of clinical readouts, and the company’s cash runway and financing plans. As a biotech, IRON can be subject to sharp share-price swings around clinical news and funding events. This profile is for general educational purposes only: it is not personal financial advice. Biotech investments can offer meaningful upside but also carry a high chance of setbacks; investors should expect volatility, review primary sources such as regulatory filings and trial data, and consider suitability relative to their own risk tolerance and time horizon.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying DISC Medicine's stock, anticipating it will rise in value.
Financial Health
DISC Medicine Inc is showing strong financial performance with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory updates can create meaningful share-price moves, though outcomes are uncertain and can vary.
Science-led growth
The company’s value ties closely to its underlying science and data; scientific progress may take time and is not guaranteed.
Long-term perspective
Biotech investments often require patience and tolerance for volatility; consider your risk profile and time horizon before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
